These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16929971)

  • 1. Myocardial contractility after in vitro treatment with class III antiarrhythmic drug Nibentan.
    Latfullin IA; Gaifullina RF; Dzhordzhikiya RK; Nigmatullina RR
    Bull Exp Biol Med; 2006 Jan; 141(1):81-3. PubMed ID: 16929971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiac effects of the class III antiarrhythmic drugs amiodarone and nibentan].
    Ugdyzhekova DS; Afanas'ev SA; Lukavskaia IA; Popov SV
    Fiziol Cheloveka; 2005; 31(4):113-8. PubMed ID: 16122045
    [No Abstract]   [Full Text] [Related]  

  • 3. [The cholinolytic activity of the new anti-arrhythmia preparation Nibentan].
    Fedorov VV; Vinogradova TM; Bogdanov KIu; Rozenshtraukh LV
    Ross Fiziol Zh Im I M Sechenova; 1999 Mar; 85(3):383-94. PubMed ID: 10494589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of class III antiarrhythmic preparation nibentan on extrasystolic and post-extrasystolic contraction of rat papillary muscle.
    Afanas'ev SA; Lukavskaya IA; Ugdyzhekova DS; Popov SV; Antonchenko IV; Abubakirova GO; Medvedev MA
    Bull Exp Biol Med; 2002 Jul; 134(1):15-7. PubMed ID: 12459857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The first original Russian class-III antiarrhythmic nibentan].
    Glushkov RG; Golitsyn SP; Dorodnikova EV; Maĭkov EB; Mashkovskiĭ MD; Merkulova IN; Rozenshtraukh LV; Ruda MIa; Skachilova SIa; Chazov EI; Iuzhakov SD
    Vestn Ross Akad Med Nauk; 1998; (11):38-41. PubMed ID: 9889704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
    Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
    J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation].
    Kaverina NV; Lyskovtsev VV; Popova EP
    Eksp Klin Farmakol; 2003; 66(1):27-33. PubMed ID: 12683077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic effects of nibentan (HE-11) on canine cardiac tissue.
    Anyukhovsky EP; Sosunov EA; Rosen MR
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1137-46. PubMed ID: 9067296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of novel class III anti-arrhythmia agents cardiocyclide and nibentan during activation of cardiac beta-adrenoreceptors].
    Turilova AI; Katsitadze NSh; Kaverina NV
    Eksp Klin Farmakol; 2002; 65(5):29-30. PubMed ID: 12596510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of a nibentan derivative LKhT53-91 on the heart electrophysiological parameters].
    Kotliarov AA; Napalkova SM; Babin VV; Skachilova SIa
    Eksp Klin Farmakol; 2002; 65(3):10-2. PubMed ID: 12227085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible involvement of sodium channel blockade of class-I-type antiarrhythmic agents in postischemic contractile recovery of isolated, perfused hearts.
    Takeo S; Tanonaka K; Hayashi M; Yamamoto K; Liu JX; Kamiyama T; Yamaguchi N; Miura A; Natsukawa T
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1403-9. PubMed ID: 7791114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of the class III antiarrhythmic drug nibentan in vagotonic atrial fibrillation].
    Popova EP; Lyskovtsev VV; Kaverina NV
    Eksp Klin Farmakol; 2006; 69(1):24-7. PubMed ID: 16579055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of the anti-arrhythmia compounds etmozin and ethacizine on the contractile activity of myocardial preparations from heart defect patients].
    Shkliar TF; Markhasin VS; Savicheskiĭ MS
    Kardiologiia; 1987 May; 27(5):71-5. PubMed ID: 3309427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of the electrophysiological properties of class iii medicinals (cardiocyclide, nibentan, sotalol) and evaluation of their efficacy in atrial fibrillation produced by auricular and vagal stimulation].
    Kaverina NV; Lyskovtsev VV; Popova EP
    Eksp Klin Farmakol; 2007; 70(1):11-6. PubMed ID: 17402585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle.
    Baskin EP; Serik CM; Wallace AA; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):406-14. PubMed ID: 1720841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of electrophysiological and mechanical effects of droxicainide and lidocaine on heart muscle isolated from rats.
    Helgesen KG; Kristiansen O; Refsum H
    Acta Pharmacol Toxicol (Copenh); 1984 Oct; 55(4):303-7. PubMed ID: 6507117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters.
    Wettwer E; Scholtysik G; Schaad A; Himmel H; Ravens U
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):480-7. PubMed ID: 1711611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of mexidol, emoxypine, and dimephosphon on electrophysiological effects of nibentan].
    Kotliarov AA; Kurkina NV; Smirnova LE; Balykova LA
    Eksp Klin Farmakol; 2002; 65(2):27-30. PubMed ID: 12109287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
    Holubarsch C; Schneider R; Pieske B; Ruf T; Hasenfuss G; Fraedrich G; Posival H; Just H
    Circulation; 1995 Nov; 92(10):2904-10. PubMed ID: 7586258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart.
    Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R
    J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.